|0.86|| +0.0095 / +1.12%|
iBio, Inc. is a biotechnology company which focuses on commercializing its proprietary technology, the iBioLaunch platform, for biologics including vaccines and therapeutic proteins. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants and human blood plasma required by other systems, to produce important biologic pharmaceuticals. iBioModulator is a proprietary technology platform that is designed to improve the potency and duration of effect of both prophylactic and therapeutic vaccines produced with any recombinant expression technology including iBioLaunch. The company was founded on April 15, 1993 and is headquartered in Newark, DE.
|Robert B. Kay||Executive Chairman & Chief Executive Officer|
|Robert L. Erwin||President|
|Mark Giannone||Chief Financial Officer|
|Terence E. Ryan||Chief Scientific Officer|
|Douglas C. Hicks||Vice President-Business Development|